R
Rafael Caparica
Researcher at Université libre de Bruxelles
Publications - 40
Citations - 492
Rafael Caparica is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 9, co-authored 31 publications receiving 283 citations. Previous affiliations of Rafael Caparica include University of São Paulo & Institut Jules Bordet.
Papers
More filters
Journal ArticleDOI
Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
TL;DR: Since the accuracy of current individual biomarkers is not optimal, a composite biomarker, including DNA, RNA and protein expression data, to more precisely assess the PI3K/AKT/mTOR pathway activation status, may arise as a promising approach.
Journal ArticleDOI
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
Rafael Caparica,Cheng Tzu Yen,Renata Coudry,Sai-Hong Ignatius Ou,Marileila Varella-Garcia,D. Ross Camidge,Gilberto de Castro +6 more
TL;DR: Two cases of MET inhibitor-sensitive NSCLC harboring high-level MET amplification (MET/CEP7 ratio ≥5) without coincident exon 14 alterations are reported, suggesting that these two methods of MET activation can produce independent MET-addicted states in NSCLCs.
Journal ArticleDOI
How I treat metastatic triple-negative breast cancer.
TL;DR: A treatment algorithm for patients with metastatic TNBC is proposed based on the currently available, most relevant literature on the topic and it is recommended that patients with a BRCA mutation and with PD-L1-negative tumours receive single-agent chemotherapy with taxanes as a first-line treatment.
Journal ArticleDOI
Pulmonary Nodules in Patients With Nonpulmonary Cancer: Not Always Metastases
Rafael Caparica,Milena Perez Mak,Claudio Henrique Rocha,Pedro Isaacsson Velho,Publio Viana,Mauricio Ruettimann Liberato de Moura,Marcos Roberto de Menezes,Marcelo B.P. Amato,Olavo Feher +8 more
TL;DR: The findings demonstrate that PNs should not be assumed to be metastases without performing a biopsy, and may lead to high rates of misdiagnosis.
Journal ArticleDOI
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials
Rafael Caparica,Marco Bruzzone,Francesca Poggio,Marcello Ceppi,Evandro de Azambuja,Matteo Lambertini +5 more
TL;DR: As adjuvant treatment of HER2-negative breast cancer, sequential A+T regimen was associated with increased risk of toxicities and no clear survival benefit as compared to 6 cycles of TC, whilst TC may be an efficacious and less toxic alternative for lower-risk patients.